Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Trump Media & Technology Group is trending as investors and the online community debate a campaign proposal to provide a significant dividend payment to every U.S. adult if Republicans retain control of Congress. Discussion is polarized, with participants arguing over the fiscal feasibility of the plan, its potential impact on the national debt, and whether it serves as a legitimate economic stimulus or an election-related bribe.

Nike is facing downward pressure amid criticism from traders over the company's recent exclusion from the S&P 100 and concerns regarding its turnaround strategy and management. While some investors see the stock as a long-term value opportunity at current levels, others are bearish, citing declining market share and brand sentiment as reasons for further potential downside.

Apple shares experienced high volatility following the product launch of its new iPhone 18 lineup and the company's first foldable device, the iPhone Duo. While the premium pricing and product innovation sparked intense debate among traders regarding consumer demand and market competition, retail sentiment remains largely bullish with expectations for strong adoption.

AeroVironment shares are receiving attention following a record fiscal first-quarter earnings report that featured a revenue beat, high book-to-bill ratios, and a record funded backlog. While some traders express frustration with the stock's recent price performance despite contract wins, others highlight the growth potential of its high-energy laser and drone defense systems.

The community is debating the potential economic impact of a proposed dividend payment to voters, while reacting to rising oil prices and Treasury yields that are pressuring equities ahead of key inflation data. Sentiment is divided between those bracing for a potential downturn and others skeptical of political promises.

AEO stock dropped following its quarterly report as investors discounted the earnings beat due to a one-time tariff refund, while the market focused on disappointing results from the namesake American Eagle brand. The community remains divided, with some traders expressing frustration over the sell-off and potential manipulation, while others view the pullback as a buying opportunity given the brand's holiday outlook.

Biohaven is trending following the disclosure that the FDA has demanded a pause in enrollment for the BHV7000-303 epilepsy trial, though dosing for current participants continues and the company maintains its 2026 data readout timeline. While some traders view the resulting dip as a buying opportunity, others are expressing concern over potential regulatory scrutiny or the impact of the enrollment pause on the stock's near-term momentum.

Xeris Biopharma is trending following a recent event detailing the clinical and commercial roadmap for its pipeline asset, XP-8121, which includes a Phase 3 trial initiation anticipated by year-end and a launch projected for 2030. While some traders expressed disappointment over the long-term timeline and are concerned about near-term expenses, others view the company's established growth in Recorlev and the multibillion-dollar potential of XP-8121 as strong long-term catalysts.

AMD shares are gaining momentum as traders react to positive commentary from CFO Jean Hu regarding an expanded total addressable market for AI chips and robust shipment projections through 2027. While community sentiment is largely bullish on growth prospects, some traders remain skeptical of current valuations, leading to debates over potential profit-taking and volatility.

Helus Pharma is trending primarily due to positive community sentiment surrounding its Phase 3 APPROACH trial for HLP003, with investors highlighting the completion of enrollment ahead of schedule and the company's $50 million underwritten offering as key developments. Traders are also speculating on potential acquisition interest, drawing comparisons to recent M&A activity in the broader psychedelic neuropsychiatry sector.